Pravastatin vs rosuvastatin
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Comparative Analysis of Pravastatin vs. Rosuvastatin
Efficacy in Lowering LDL Cholesterol
Rosuvastatin Superior in LDL-C Reduction
Multiple studies have demonstrated that rosuvastatin is more effective than pravastatin in lowering low-density lipoprotein cholesterol (LDL-C). In a 52-week trial, rosuvastatin at doses of 5 mg and 10 mg reduced LDL-C by 39.1% and 47.4%, respectively, compared to a 26.5% reduction with 20 mg of pravastatin. Another study showed that rosuvastatin reduced LDL-C by 26% more than pravastatin across various doses. Additionally, in HIV-1-infected patients, rosuvastatin 10 mg/day was more effective than pravastatin 40 mg/day, achieving a 37% reduction in LDL-C compared to 19% with pravastatin.
Achievement of Lipid-Lowering Goals
Rosuvastatin also outperforms pravastatin in helping patients achieve lipid-lowering goals. In a pooled analysis, 86% of patients treated with rosuvastatin 10 mg achieved the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) LDL-C goals, compared to only 49% of those treated with pravastatin 20 mg. Similarly, in another study, 88% of patients who switched to rosuvastatin 10 mg from pravastatin 40 mg achieved their LDL-C goals, compared to 66% who remained on pravastatin.
Metabolic Effects
Differential Impact on Insulin Sensitivity and Adiponectin Levels
Rosuvastatin and pravastatin have different metabolic effects. Rosuvastatin therapy has been associated with increased fasting insulin levels and decreased insulin sensitivity, as well as reduced plasma adiponectin levels. In contrast, pravastatin therapy decreased fasting insulin levels and increased insulin sensitivity and plasma adiponectin levels. These differences may be clinically relevant for patients prone to metabolic diseases.
Safety and Tolerability
Comparable Tolerability
Both rosuvastatin and pravastatin are generally well-tolerated. In various studies, no significant differences in severe adverse events were attributed to either statin, and both were well-tolerated over the study periods .
Conclusion
In summary, rosuvastatin is more effective than pravastatin in lowering LDL-C and helping patients achieve lipid-lowering goals. However, rosuvastatin may have less favorable metabolic effects compared to pravastatin, particularly in terms of insulin sensitivity and adiponectin levels. Both statins are well-tolerated, making them viable options depending on the specific needs and metabolic profiles of patients.
Sources and full results
Most relevant research papers on this topic